This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Read, J. S. Articles by Stoszek, S. K. Search for Related Content PubMed PubMed Citation Articles by Read, J. S. Articles by Stoszek, S. K. Social Bookmarking                         What's this?

Safety of HIV-1 Perinatal Transmission Prophylaxis With Zidovudine and Nevirapine in Rural South India

Pediatric, Adolescent, and Maternal AIDS Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, jennifer_read{at}nih.gov

N.M. Samuel, PhD

Tamil Nadu Dr. M.G.R. Medical University, Chennai, India

S. Parameshwari, MBBS

Tamil Nadu Dr. M.G.R. Medical University, Chennai, India

Shoba Dharmarajan, MBBS

Tamil Nadu Dr. M.G.R. Medical University, Chennai, India

Hannah M. Van Hook, BS

Westat, Rockville, Maryland

S. Mini Jacob, MD

Tamil Nadu Dr. M.G.R. Medical University, Chennai, India

Viju Junankar, BS

Westat, Rockville, Maryland

James Bethel, PhD

Westat, Rockville, Maryland

Jiahong Xu, MPH

Westat, Rockville, Maryland

Sonia K. Stoszek, PhD

Westat, Rockville, Maryland

Background: The authors assessed acceptance and safety of, and adherence to, perinatal HIV-1 transmission prophylaxis at 2 public hospitals in rural Tamil Nadu, India. Methods: Eligible HIV-1—infected women were offered zidovudine (ZDV) beginning at 28-weeks gestation until delivery. Their infants received ZDV for 6 weeks. A subsequent revision to the protocol added 1 dose of nevirapine (NVP) for mother and infant. Results: Sixty of 67 women (90%) met inclusion criteria for the cohort study. Thirty-four of 36 eligible women and all 19 eligible live born infants received prophylaxis on study. Infant, but not maternal, adherence to ZDV varied by antiretroviral prophylaxis group (those receiving combined prophylaxis with ZDV and NVP had lower median adherence) (P = .02). Neutropenia (usually transient) was the most common severe adverse event. Only 1 of 5 women with neutropenia possibly related to ZDV permanently discontinued ZDV. ZDV was not discontinued for any infant. Conclusion: With the exception of neutropenia, usually transient and always without clinical consequences, long-term ZDV (with or without NVP prophylaxis) is well tolerated.

Key Words: HIV-1 • antiretroviral prophylaxis • India • mother-to-child transmission • safety

Journal of the International Association of Physicians in AIDS Care (JIAPAC), Vol. 6, No. 2, 125-136 (2007)
DOI: 10.1177/1545109707301248


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?